{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.4","upperLimit":"81.8","value":"68.9"},{"groupId":"OG001","lowerLimit":"61.6","upperLimit":"89.2","value":"77.5"},{"groupId":"OG002","lowerLimit":"85.4","upperLimit":"97.4","value":"93.0"}]}],"title":"Independent Central Review"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.1","upperLimit":"86.7","value":"75.5"},{"groupId":"OG001","lowerLimit":"62.4","upperLimit":"89.4","value":"78.0"},{"groupId":"OG002","lowerLimit":"87.6","upperLimit":"98.2","value":"94.5"}]}],"title":"Investigator Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing(immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG000","title":"Cohort 1: HER2 Overexpressing"},{"description":"Participants with HER2-overexpressing (immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG001","title":"Cohort 1a: HER2 Overexpressing"},{"description":"Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG002","title":"Cohort 2: HER2 Mutated"}],"paramType":"NUMBER","populationDescription":"Disease control rate was assessed in the Full Analysis Set at data cut-off date of 03 May 2021.","reportingStatus":"POSTED","timeFrame":"From first dose, up to 36 months (data cut-off)","title":"Percentage of Participants With Disease Control Rate (DCR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}